Table 4.
Deregulated miRNAs in selected studies in HGSOC.
| Reference | Effect | Experimental Design | Main Deregulated miRNAs in Patients |
|---|---|---|---|
| [130] | Susceptibility to oncogenic mutations and histologic differentiation. FTE cells increase CA-125 upon pre-miR-200 transfection. |
HGSOC, STIC and FTE vs. OSE | ↑ miR-200a, miR-200b, miR-141 and miR-429 and miR-205 |
| [133] | Five miRNAs associated with cisplatin resistance EMT phenotype associated with higher chemoresistance Two pathways associated with overall patient survival (TGF/WNT and Regulation of EMT) |
Four ovarian cancer cell lines, public ovarian cancer dataset | Positively correlated namely miR-496, miR-485-5p, let-7g and miR-152 Negatively correlated miR-27b |
| [134] | EMT phenotype, cisplatin resistance and worse prognosis | HGSOC tissue and ovarian cancer cell lines (chemosensitive and chemoresistant) | ↓ miR-186, ↑ miR-200 family (significantly miR-141 and miR-200a) |
| [135] | Platinum resistance, related to EMT and stemness | Exploratory study based on nine published gene sets associated with platinum resistance in ovarian cancer. | ↓ miR-17-92 cluster, let-7 family members |
| [136] | Stronger EMT phenotype and paclitaxel resistance | Two ovarian cancer cell lines (sensitive and resistant to paclitaxel and carboplatin) | ↓ miR-200s (miR-200a, miR200b, miR-200c, miR-429 and miR-141) |
| [138] | Increased chemoresistance by regulation of the VEGFB and VEGFR2 pathway | 198 serous epithelial ovarian carcinomas, six epithelial ovarian carcinoma cell lines | ↓ miR-484 (tumour angiogenesis), miR-642, miR-217 |
| [139] | Poor prognosis, increased placlitaxel resistance | HGSOC tissues relative to normal control tissues. Placlitaxel resistant ovarian cell lines. | ↓ miR-136 |
| [140] | Decreased cisplatin resistance by PARP1 regulation | Cisplatin-resistant and cisplatin-sensitive ovarian cancer cell lines | ↓ miR-216b |
| [141] | Longer progression-free survival (PFS), increased platinum sensitivity to cisplatin and PARP inhibitors by directly targeting BRCA1 | Serous ovarian cancer patients and tumour xenografts | ↑ miR-9 |
↑, up-regulated levels; ↓, down-regulated levels; BRCA1, Breast Cancer type 1 susceptibility protein; EMT, epithelial-to-mesenchymal transition; VEGFB, vascular endothelial growth factor B; VEGFR2, vascular endothelial growth factor receptor 2; FTE, Fallopian Tube Epithelial; HGSOC, high-grade serous ovarian cancer; OSE, ovarian surface epithelium; PARP1, Poly [ADP-ribose] polymerase 1; STIC, Serous Tubal Intraepithelial Carcinoma, TGF, Transforming Growth Factor; Wnt, Wingless-related integration site.